McKesson Corporation (MCK)
Health Care · healthcare distribution and services · NYSE
A global leader in pharmaceutical distribution and healthcare technology services, connecting biopharma, providers, and patients to improve care outcomes.
What McKesson Corporation does
McKesson is a diversified healthcare services leader that distributes pharmaceuticals, medical-surgical supplies, and laboratory equipment. The company provides a range of services to biopharma companies, care providers, and pharmacies, including oncology practice support, medication access and adherence technology, and specialty drug distribution. Its operations are organized into four primary segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
Themes: pharmaceutical supply chain, oncology and specialty care services, healthcare automation and digital health, medication access and affordability, non-acute care market services
Fundamentals
- Price$858.90 as of 2026-08-21 close
- Market cap$100.1B as of 2026-08-21
- 1-year return+21.7% 2025-08-21 close $706.00 → 2026-08-21 close $858.90
- P/E21.89 as of 2026-08-24
- Net margin+1.1% as of 2026-08-24
- Gross margin+3.6% as of 2026-08-24
- ROE+39.4% as of 2026-08-24
- Debt / equity1.29 as of 2026-08-24
- Revenue growth (YoY)+8.8% as of 2026-08-24
- Revenue CAGR (3y)+13.4% SEC XBRL
- Beta0.30 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.5%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How MCK compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MCK is not currently in any published Top 10 list. Its scores are below.
Long-term score
53.2 #385 of 987 scored · #23 of 57 in Health Care
Valuation 75th (price to earnings 23 (within its sector)) and capital return 71st (consecutive years of dividend increases 5 years); weakest is financial health (17th, free cash flow margin 1.5%, debt to equity 1.3).
Short-term score
57.4 #345 of 1,704 scored · #67 of 240 in Health Care
Volume and participation 96th: trading volume is about normal versus its 30-day average; setup 61st: no fresh 20-day breakout up or down; weakest is catalysts 37th: the analyst consensus rating has softened toward "sell" since the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2026)
Covered by reported results. In FY2026, MCK's dividend was covered by reported results (earnings payout 8%, free-cash-flow payout 7%). This describes past coverage, not a forecast.
- Earnings payout8% dividends / net income
- Free-cash-flow payout7% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2026 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How McKesson Corporation looks technically
McKesson Corporation (MCK) is trading 2.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 56 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day high about 9 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 2.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +2.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $821.25 | $821.25 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $840.96 | $840.96 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 912.5. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 56 trading days ago — a "death cross", a bearish long-term signal | 56 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 2.1% above | +2.1% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend) | 19.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 52.3 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($810.88 to $912.50) — its "stochastic" reading is 47 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 47.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $999.00 | $999.00 |
|---|---|---|
| From the 52-week high | it is 14.0% below its 52-week high (its highest price of the past year) | -14.0% |
| Above the 52-week low | it is 28.7% above its 52-week low (its lowest price of the past year) | +28.7% |
| Below the 52-week high | it is 14.0% below its highest point of the past year | 14.0% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $999.00 (set on 2026-03-03) | $999.00 |
| Given back of the 52-week move | over the past year its closes ranged ($676.91 to $995.69), and it has given back roughly a third of its rise from last year’s low — 43% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $788.48 to $798.68. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 42.9% |
| From the all-time high | it is 14.0% below its all-time high | -14.0% |
| Nearest price level | it is trading 0.5% below a resistance level at $863.50 — a price it turned at twice since 2025-11-07, most recently on 2026-07-17. Since 2024-08-21 it has 13 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.5% |
| All-time low | its lowest closing price on record is $28.27 (set on 2008-11-20) | $28.27 |
| Above the all-time low | it is 2938.2% above its all-time low | +2,938% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 75% of it) | 25th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $26.01 between its high and its low — about 3.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $26.01 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $827.09 and $902.13 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $827.09 – $864.61 – $902.13 |
| Typical daily range (% of price) | its price moves about 3.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.0% |
| Stretch from the 200-day average | it is trading 0.7 daily ranges above its 200-day average price (2.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.72× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.5% since the prior reading | -0.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.08 toward sell |
Candlestick patterns
1
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Gap filled | a 2.2% gap down opened on 2026-07-30 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it took 5 sessions to close | 11 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.3 percentage points (the stock gained 3.6% while the market gained 2.3%) | +1.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 9.0 percentage points (the stock gained 12.1% while the market gained 3.1%) | +9.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.4 percentage points (the stock lost 9.3% while the market gained 11.1%) | -20.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 1.2 percentage points (the stock gained 21.7% while the market gained 20.5%) | +1.2% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.1% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.1% of the share price. | +7.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $832.24 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +3.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $868.29 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -1.1% |
Price levels it has turned at before
MCK last closed at $858.90 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $863.50 | Resistance | 0.5% above the last close | turned there twice · 2025-11-07 to 2026-07-17 |
| $846.15 | Support | 1.5% below the last close | turned there three times · 2026-01-07 to 2026-04-07 |
| $891.41 | Resistance | 3.8% above the last close | turned there twice · 2025-11-26 to 2026-04-02 |
| $824.93 | Support | 4.0% below the last close | turned there twice · 2025-12-12 to 2026-07-08 |
| $909.76 | Resistance | 5.9% above the last close | turned there three times · 2026-03-06 to 2026-08-06 |
| $806.08 | Support | 6.2% below the last close | turned there three times · 2026-01-21 to 2026-08-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $912.50.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · trendless / choppy (low ADX) · lagging the market · Trading above the Ichimoku cloud · Near a support level (sitting on a price it has bounced off before) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.61 mean, 1=Strong Buy…5=Strong Sell) — 16 analysts
- Mean price target$986.94 range $845.00 – $1,080.00; median $1,000.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MCK
- Consensus EPS estimate$10.77 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a limited number of major pharmaceutical manufacturing customers and retail pharmacy chains.","Significant exposure to complex government regulations, pricing pressures, and evolving healthcare policies in the U.S. and Canada.","Operating within an industry subject to frequent litigation and legal investigations related to drug distribution."]
What changed in the latest 10-Q
AI-assisted comparison of MCK's 10-Q filed 2026-02-04 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-02-04) adds: 'On January 30, 2026, we completed the sale of our Norway disposal group.' regarding the Norway operations transaction completion.
- Newer filing (2026-02-04) adds statement that Norway operations were 'previously included in the former International reportable segment' (emphasizing 'former').
- Removed:
- Older filing (2025-11-06) states Norway transaction 'is subject to customary closing conditions, including receipt of required regulatory approvals' — this contingency language is removed in newer filing.
- Older filing (2025-11-06) references 'During the six months ended September 30, 2025' for Norway transaction — newer filing updates timeframe to 'During the nine months ended December 31, 2025'.
- Reworded:
- PRISM Vision acquisition price changed from '$871 million' (older, 2025-11-06) to '$875 million' (newer, 2026-02-04).
- Norway operations description changed from 'were previously included in the International reportable segment and are now included in Other' (older) to 'were previously included in the former International reportable segment, but are now included in Other' (newer) — addition of 'former' and 'but'.
- Segment determination language changed from 'reflect the Company's new segment structure' (older) to 'reflect our new segment structure' (newer).
- Notes:
- PRISM Vision acquisition price difference ($871M vs $875M) may reflect correction or reporting adjustment rather than transaction change.
- The newer filing text appears truncated at the end of the Core Ventures section, limiting full comparison of that acquisition description.
Risk Factors
- Added:
- Nine months ended December 31, 2025 financial data added (newer filing covers nine months vs. six months in older filing)
- LIFO credit of $10 million for three months ended December 31, 2025 and credit of $28 million for nine months ended December 31, 2025 disclosed
- Detailed LIFO accounting methodology explanation added, including impact of year-end inventory quantities, product mix, and manufacturer pricing practices
- Claims and litigation charges, net of ($2) million for nine months ended December 31, 2025 added
- Removed:
- Antitrust legal settlement gains amounts changed: $15 million and $31 million for three months (newer) vs. 'immaterial gains and $63 million' for three months (older); $23 million and $184 million for nine months (newer) vs. '$8 million and $153 million' for six months (older)
- LIFO charge of $89 million for three months ended December 31, 2024 and charge of $85 million for nine months ended December 31, 2024 disclosed (newer filing)
- Detailed explanation of Canadian retail disposal group remeasurement charges removed
- Rite Aid bankruptcy credit discussion removed
- Acquisition-related SDG&A impact discussion removed
- Detailed opioid-related claims charge explanation removed
- Reworded:
- Risk factor language changed from 'Changes in U.S. federal regulatory posture and law' (older) to 'Changes in regulatory posture and law' (newer), removing 'U.S. federal' qualifier
- Period references changed from 'three and six months ended September 30, 2025' (older) to 'three months ended December 31, 2025' and 'nine months ended December 31, 2025' (newer), reflecting different reporting periods
- Antitrust settlement disclosure wording changed from 'We recognized immaterial gains and $63 million' (older, three months) to 'We recognized gains of $15 million and $31 million' (newer, three months)
- Notes:
- The two filings report different fiscal periods (nine months ended December 31, 2025 vs. six months ended September 30, 2025), making direct financial comparisons of period-specific metrics not directly comparable
- The newer filing text appears truncated at the end ('Total operating expenses were impacted by the following s'), preventing full assessment of all changes in that section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($268590) — 1 selling insider
- Last 90 days0 buys · 8 sells ($19M) — 5 selling insiders
- Last 180 days0 buys · 10 sells ($24M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-10. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MCK's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 25 matched disclosures for MCK from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding MCK as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 21,228,098
- Reported value $18,374,612,578
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MCK had 3,613,111 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MCK had 3.10% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.84 days to cover at the same settlement.
- Reported short interest (shares) 3,613,111
- Short interest (% of shares outstanding) 3.10%
- Prior settlement (shares) 3,878,060
- Reported change -6.83%
- Days to cover (reported) 3.84
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AmerisourceBergen (now Cencora, COR)
- Cardinal Health (CAH)
- CVS Health (CVS)
- Walgreens Boots Alliance (WBA)
- Henry Schein (HSIC)
- Patterson Companies (PDCO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MCK vs…
McKesson Corporation is found in…
MCK shows up in…
Frequently asked questions
What does McKesson Corporation (MCK) do?
McKesson is a diversified healthcare services leader that distributes pharmaceuticals, medical-surgical supplies, and laboratory equipment. The company provides a range of services to biopharma companies, care providers, and pharmacies, including oncology practice support, medication access and adherence technology, and specialty drug distribution.
What sector is McKesson Corporation (MCK) in?
McKesson Corporation (MCK) is classified in the Health Care sector. Its industry is healthcare distribution and services. It trades on NYSE.
Does MCK pay a dividend?
Yes — McKesson Corporation (MCK) pays a dividend, with an indicated yield of about 0.54% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are McKesson Corporation's (MCK) competitors?
Notable peers of McKesson Corporation (MCK) include AmerisourceBergen (now Cencora, COR), Cardinal Health, CVS Health, Walgreens Boots Alliance and Henry Schein. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in MCK?
Yes — we hold 25 matched STOCK Act disclosures for MCK from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is McKesson Corporation (MCK) overbought or oversold right now?
McKesson Corporation (MCK) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MCK come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.